Dr. Bradley A. Mcgregor, MD

Medicare patients and services

Medicare patients, 2024

299

Services billed

789

Patients’ average age

73

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 12 companies reported 38 payments worth $22,457 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $1,606,931 in research payments for these studies, mostly to the institutions running them.

• A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
  Exelixis Inc.
• A Phase 2 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma
  Exelixis Inc.
• Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
  Aveo Pharmaceuticals, Inc. · Recruiting · NCT06661720
• Short Term Intensified Pembrolizumab and Tivozanib for High-Risk RCC (STRIKE)
  Aveo Pharmaceuticals, Inc.
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
  Aveo Pharmaceuticals, Inc. · Completed · NCT04987203
• A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
  Exelixis Inc.
• A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS…
  E.r. Squibb & Sons, L.l.c.
• A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Meta…
  E.r. Squibb & Sons, L.l.c.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Boston

• Janet L. Abrahm, MD
• Thomas A. Abrams, M.D.
• Jeremy S. Abramson, MD
• Nana O. Addo-tabiri, MD
• Adeboye H. Adewoye, M.D.
• Neeraj Agarwal, MD
• Andrew J. Aguirre, MD, PHD
• Inhye Ahn, M.D.